Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA RECEIVES US PATENT
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that the US
patent number 8,771,701 titled Compositions for immunotherapy and uses thereof , which protects the Company s CVac technology, has been granted by the United States Patent and Trademark Office (USPTO).
Prima has also received a patent term adjustment of 1,409 days for US 8,771,701, extending the patent expiry date for the US market to August 2022.
Chief Executive Officer of Prima, Mr Marc Voigt said: The grant of this key US patent with a patent term adjustment of almost four years is an important
value proposition for Prima. The patent term can potentially be further extended by up to five years if CVac receives market approval before it expires, which would provide the Company with essential protection over its commercial development well
The patent grant protects the method of composition and the method of use of CVac, which is formulated in a patient s own
dendritic cells and then reinjected back into the patient to generate a cytotoxic T cell response against the mucin 1 antigen. CVac is a personalised immunotherapy composed of a patient s own dendritic cells pulsed with the cancer antigen mucin
1, conjugated to oxidised mannan.
The patent grant follows receipt of the Notice of Allowance from the USPTO in relation to Patent Application 11/561,204
as announced on 26 May 2014. It completes the granting of all patents relevant to the CVac technology. Other territories that have received patent approval include Australia, Canada, Europe and Japan.
Prima BioMed is a globally active
leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize
value to shareholders. Prima s lead product is CVac , an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889
For further information please contact:
Adam Holdsworth, ProActive Capital
+1 (646) 862 4607; adamh@proactivecapital.com
Australia Investor/Media:
Mr Matthew Gregorowski,
Citadel Communications
+61 (0) 422 534 755; mgregorowski@citadelpr.com.au
Europe Investor/Media:
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889